Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.
Hematology/Oncology February 12th 2024
In this Phase 3 trial, resmetirom demonstrated a notable capacity to induce NASH resolution and improve liver fibrosis, offering hope for a therapeutic breakthrough in a field with limited treatment options. This study emphasizes the importance of advancing research in liver-directed therapies for NASH.
Gastroenterology February 12th 2024
Psychiatrist.com
In a phase 3 study, iloperidone demonstrated a significant improvement in treating bipolar mania, marked by a reduction in the Young Mania Rating Scale (YMRS) scores.
Psychiatry February 6th 2024
NEJM Evidence
In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.
Oncology, Medical February 5th 2024
Oncology News Central (ONC)
In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.
Annals of Internal Medicine
In a recent study assessing chronic insomnia treatments in hemodialysis patients, no significant difference was observed between CBT-I, trazodone, and placebo in improving Insomnia Severity Index scores. This highlights a critical need for alternative therapeutic approaches in this unique patient population.
Nephrology January 24th 2024